Immune receptors encoded by genes in the leukocyte receptor complex region on human chromosome 19q13.4. Common names and CD designations of the receptors are indicated. Functions and associations with adapter proteins are implied based on structural characteristics of the receptors, but have only been validated experimentally for a few of the receptors, usually when a ligand has been identified. As indicated, certain KIR2DL recognize a dimorphic polymorphism in HLA-C at positions 77 and 80 in the α1 helix of the class I heavy chain. N77K80 and S77N80 refer to the amino acids (single letter code) present at residues 77 and 80 in HLA-C, conferring specificity for the indicated KIR. * = KIR2DL2 and KIR2DL3 are alleles of the same locus; KIR3DL1 and KIR3DS1 are alleles of the same locus. All other receptors listed are encoded by separate genes, although many of these genes also demonstrate allelic polymorphism.
Names . | CD . | Function . | Signaling . | Ligand . |
---|---|---|---|---|
ILT5 / LIR3 / LILRB3 | CD85a | Inhibition | ITIM | |
ILT8 / LILRB6 | CD85b | Activation | FcεRIγ | |
LIR8 / LILRB5 | CD85c | Inhibition | ITIM | |
ILT4 / LIR2 / LILRB2 | CD85d | Inhibition | ITIM | HLA class I |
ILT6 / LIR4 / LILRA3 | CD85e | Soluble | - | |
ILT11 / LILRB7 | CD85f | Activation | FcεRIγ | |
ILT7 / LILRA4 | CD85g | Activation | FcεRIγ | |
LAIR-1 | Inhibition | ITIM | ||
LAIR-2 | Soluble receptor | |||
ILT1 / LIR7 / LILRA2 | CD85h | Activation | FcεRIγ | |
LIR6 / LILRA1 | CD85i | Activation | FcεRIγ | |
ILT2 / LIR1/ LILRB1 | CD85j | Inhibition | ITIM | HLA class I, CMV UL18 |
ILT3 / LIR5/ LILRB4 | CD85k | Inhibition | ITIM | |
ILT9 / LILRA6 | CD85l | Pseudogene | ||
ILT10 / LILRA5 | CD85m | Activation | FcεRIγ | |
KIR3DL3 | CD158z | Inhibition | ITIM | |
KIR2DL3* | CD158b2 | Inhibition | ITIM | HLA-C S77/N80 |
KIR2DL2* | CD158b1 | Inhibition | ITIM | HLA-C S77/N80 |
KIR2DL1 | CD158a | Inhibition | ITIM | HLA-C N77/K80 |
KIR2DL4 | CD158d | Inhibition/ Activation? | ITIM / ? | |
KIR3DL1* | CD158e1 | Inhibition | ITIM | HLA-Bw4 |
KIR3DS1* | CD158e2 | Activation | DAP12 | |
KIR2DL5A | CD158f | Inhibition | ITIM | |
KIR2DL5B | Inhibition | ITIM | ||
KIR2DS3 | Activation | DAP12 | ||
KIR2DS5 | CD158g | Activation | DAP12 | |
KIR2DS1 | CD158h | Activation | DAP12 | HLA-C, weakly |
KIR2DS2 | CD158j | Activation | DAP12 | |
KIR2DS4 | CD158i | Activation | DAP12 | HLA-C, weakly |
KIR3DL2 | CD158k | Inhibition | ITIM | HLA-A? |
FcαR | CD89 | Activation | FcεRIγ | IgA |
NKp46 | Activation | FcεRIγ, ζ |
Names . | CD . | Function . | Signaling . | Ligand . |
---|---|---|---|---|
ILT5 / LIR3 / LILRB3 | CD85a | Inhibition | ITIM | |
ILT8 / LILRB6 | CD85b | Activation | FcεRIγ | |
LIR8 / LILRB5 | CD85c | Inhibition | ITIM | |
ILT4 / LIR2 / LILRB2 | CD85d | Inhibition | ITIM | HLA class I |
ILT6 / LIR4 / LILRA3 | CD85e | Soluble | - | |
ILT11 / LILRB7 | CD85f | Activation | FcεRIγ | |
ILT7 / LILRA4 | CD85g | Activation | FcεRIγ | |
LAIR-1 | Inhibition | ITIM | ||
LAIR-2 | Soluble receptor | |||
ILT1 / LIR7 / LILRA2 | CD85h | Activation | FcεRIγ | |
LIR6 / LILRA1 | CD85i | Activation | FcεRIγ | |
ILT2 / LIR1/ LILRB1 | CD85j | Inhibition | ITIM | HLA class I, CMV UL18 |
ILT3 / LIR5/ LILRB4 | CD85k | Inhibition | ITIM | |
ILT9 / LILRA6 | CD85l | Pseudogene | ||
ILT10 / LILRA5 | CD85m | Activation | FcεRIγ | |
KIR3DL3 | CD158z | Inhibition | ITIM | |
KIR2DL3* | CD158b2 | Inhibition | ITIM | HLA-C S77/N80 |
KIR2DL2* | CD158b1 | Inhibition | ITIM | HLA-C S77/N80 |
KIR2DL1 | CD158a | Inhibition | ITIM | HLA-C N77/K80 |
KIR2DL4 | CD158d | Inhibition/ Activation? | ITIM / ? | |
KIR3DL1* | CD158e1 | Inhibition | ITIM | HLA-Bw4 |
KIR3DS1* | CD158e2 | Activation | DAP12 | |
KIR2DL5A | CD158f | Inhibition | ITIM | |
KIR2DL5B | Inhibition | ITIM | ||
KIR2DS3 | Activation | DAP12 | ||
KIR2DS5 | CD158g | Activation | DAP12 | |
KIR2DS1 | CD158h | Activation | DAP12 | HLA-C, weakly |
KIR2DS2 | CD158j | Activation | DAP12 | |
KIR2DS4 | CD158i | Activation | DAP12 | HLA-C, weakly |
KIR3DL2 | CD158k | Inhibition | ITIM | HLA-A? |
FcαR | CD89 | Activation | FcεRIγ | IgA |
NKp46 | Activation | FcεRIγ, ζ |